Objective: To examine the rates and patterns of new psychoactive substance (NPS) use amongst regular psychostimulant users (RPU) in Australia.
Introduction
Over the past decade, countries worldwide have witnessed the rapid emergence of substances collectively referred to as 'new psychoactive substances' (NPS). NPS are substances which often do not fall under international drug controls but which may pose a public health threat (United Nations Office on Drugs and Crime (UNODC), 2013). The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has identified 13 categories of NPS: aminoindanes, arylalkylamines, arylcyclohexylamines, benzodiazepines, synthetic cannabinoids, synthetic cathinones, indolalkylamines (i.e. tryptamines), opioids, phenethylamines, piperazine derivates, piperidines and pyrrolidines, plants and extracts, and others (EMCDDA, 2006 (EMCDDA, , 2007 (EMCDDA, , 2008 (EMCDDA, , 2009 (EMCDDA, , 2010 (EMCDDA, , 2011 (EMCDDA, , 2012 (EMCDDA, , 2013 (EMCDDA, , 2014 (EMCDDA, , 2015 . In 2014, over 450 NPS were being monitored by EMCDDA, the majority of which fell into the synthetic cathinone and synthetic cannabinoid categories (EMCDDA, 2015) .
The extent to which NPS are used globally remains unclear, with prevalence rates varying considerably across countries. Data from the European Union indicated that, in 2014, 3% of people aged 15-24 had used an NPS in the past year, with use highest in Ireland, Spain and France (5% respectively) (European Commission, 2014) . The Crime Survey for England and Wales found that 0.6% and 0.5% of 16-59 year olds reported past year use of mephedrone and salvia respectively (Home Office, 2014) ; in the United States, 4.8% of adolescents (grade 8-12) reported past year use of synthetic cannabinoids in 2014 and 0.8% reported use of synthetic stimulants (Miech et al., 2014) . In Australia, the 2013 National Drug Strategy Household Survey showed that 1.2% of the general population had used synthetic cannabinoids in the last 12 months, and 0.4% had used another NPS (Australian Institute of Health & Welfare (AIHW), 2014).
Whilst general population estimates appear to be relatively low, rates of NPS use are elevated amongst high risk groups, such as illicit drug users and those engaged in the night time economy (Bretteville-Jensen et al., 2013; Bonar et al., 2014; Burns et al., 2014; Kelly et al., 2013; Moore et al., to the NPS being used.
The public health risks associated with NPS are many and varied. Synthetic cannabinoids, for example, have been associated with acute and persistent psychosis, tachycardia, agitation, hallucinations, hypertension, vomiting, chest pain, seizures and myoclonia (Every-Palmer, 2010; Hermanns-Clausen, 2012) ; whilst mephedrone has been shown to impair working memory (Freeman et al., 2012) , and has been associated with jaw clenching, reduced appetite, insomnia, agitation, tachycardia and dependence (Dargan et al., 2010; Dargan et al., 2011; Winstock et al., 2011) . In addition, data from the Global Drug Survey showed that the risk of seeking emergency medical treatment was 30 times higher amongst synthetic cannabinoid users than herbal cannabis users, whilst 'other' NPS users were about three times more likely to seek emergency medical treatment compared to traditional illicit drug users (Winstock, 2015) .
Given the different risk profiles associated with NPS use, it is essential to obtain a more nuanced understanding of who are most at risk for using these substances. This will improve our ability to tailor harm reduction messages to the appropriate target groups. Subsequently, the aims of this paper are twofold: 1) To examine the prevalence of NPS use amongst a sample of regular psychostimulant users (RPU) in Australia, from 2010 Australia, from -2015 2) To determine whether correlates of use vary across the following five NPS classes; phenethylamines, tryptamines, synthetic cannabinoids, synthetic cathinones, and 'poly' NPS (i.e. use of more than one NPS class).
Method

Study design
This paper uses six years of data (2010) (2011) (2012) (2013) (2014) (2015) from the Ecstasy and related Drugs Reporting System (EDRS) (for full protocol details, see Sindicich & Burns, 2015) . The EDRS is a national monitoring study aimed at detecting emerging trends in illicit drug markets and has been conducted annually in all Australian jurisdictions since 2003. The EDRS has received ethical approval from the University of New South Wales Human Research Ethics Committee (HC10071, HC15015), as well as from the relevant ethics committees in each jurisdiction.
Participants and procedure
EDRS participants (hereafter referred to as 'regular psychostimulant users' (RPU)) comprised a nonrandom self-selected sample recruited annually through street-press advertisements, online forums and peer referral. Eligibility criteria were; at least monthly use of ecstasy or psychostimulants in the preceding six months, 16 years of age or older, and residence in the city of interview for at least 12 months prior to the interview. Face-to-face one-hour structured interviews were conducted by trained interviewers at a negotiated time and location. All information was confidential and anonymous.
Measures relevant to the current study
Outcome variables
From 2010-2015, participants were asked about their past six month use of 26 specific NPS (see Table 1 for a full list, with street names provided in brackets); an open text 'other' option was provided to capture any additional NPS not listed in the survey. These NPS have been categorised into eight of the thirteen categories identified by the EMCDDA; namely synthetic cannabinoids, synthetic cathinones (i.e. stimulant and entactogen phenethylamines), phenethylamines (i.e. psychedelic phenethylamines), tryptamines, piperazines, plant and extracts, aminoindanes and arylcyclohexylamines.
Correlates
In addition to demographic questions (i.e. age, sex, sexual orientation, employment and educational status), participants were asked about their past six-month use of licit and illicit substances; the total number of illicit drug classes used in the past six months (excluding NPS) was used to measure levels of poly drug use (maximum of 17 drug classes). Participants completed the 5-item Severity of Dependence Scale (SDS; Gossop et al., 1995) in relation to ecstasy use, whereby a cut-off score of ≥3 was considered indicative of ecstasy dependence (Bruno et al., 2011) . Participants were also asked if they had binged on stimulants in the past six months (defined as the use of stimulants for 48 hours or more without sleep).
The Alcohol Use Disorders Identification Test (AUDIT) was administered to identify participants with potential alcohol-related problems (Saunders et al., 1993) . A cut-off score of ≥16 was used to measure hazardous and harmful alcohol use (Babor & Higgins-Biddle, 2000) . From its inception, the EDRS has measured crime using the Criminality Scale of the Opiate Treatment Index (OTI; Darke et al., 1991) . This scale gathers self-report data on four types of crime: property crime; dealing; fraud; and violent crime (in the month preceding interview).
Across all years, participants were administered the Kessler 10 (K10) Psychological Distress Scale to assess psychological distress (Kessler et al., 2003) . The K10 is a 10-item screening tool utilizing a fivepoint response scale (1 'none of the time' to 5 'all of the time'); a cut-off score of ≥22 (score range 10-50) was used to measure high to very high psychological distress (Andrews & Slade, 2001) .
Participants also answered self-report questions about their mental health over the previous sixmonth period.
Participants were asked if they had participated in the EDRS previously; this question was used to exclude repeat participants.
Statistical analysis
Rates of NPS use
Rates of use were generated by collapsing the various NPS to determine if participants had consumed 'any' NPS in the six months preceding interview. Using the groupings identified by the EMCDDA, rates of use were then broken down into the following classes; synthetic cannabinoids, synthetic cathinones, phenethylamines, tryptamines, piperazines, plants and extracts, aminoindanes and arylcyclohexylamines. Paired comparisons of percentages reporting use were made across adjacent years (e.g. 2010-2011; 2011-2012) with 95% confidence intervals (95% CI) reported.
Correlates of NPS use
Socio-demographic profiles were compared across the four most commonly used NPS classes (i.e. synthetic cathinones, synthetic cannabinoids, phenethylamines and tryptamines). The sample was divided into groups based on use of these substances in the six months preceding interview and compared to non NPS using participants (e.g. recent cathinone use only vs. no recent NPS use). In order to maintain distinct groups of NPS users (see Supplementary Material, Table 8 for overlap between NPS classes), participants who had used more than one NPS class were excluded from this analysis and included in the 'poly' NPS use group. As synthetic cannabinoids were first specifically asked about in 2011, this analysis was limited to 2011-2015 data (with all repeat participants excluded from 2012-2015 data).
Between-group comparisons of categorical variables were analysed using odds ratios (OR) with 95% confidence intervals reported. For normally distributed continuous variables, t-tests were employed with means and standard deviations (SDs) reported. The Benjamini-Hochberg procedure was applied to control the false discovery rate and was used because it yields much greater power than the widely applied Bonferroni technique (Thissen et al., 2002) .
Variables found to be significant based on bivariate comparisons were entered into a multivariable logistic regression model, which estimated adjusted odds ratios (AOR) after controlling for potential confounders. To allow comparability across the five NPS categories, the same variables were entered into each of the regression models (this allows us to determine if the same variables are associated with different NPS classes and if they differ in magnitude). Associations were set for statistical significance at p < 0.05. All analyses were conducted using IBM SPSS Statistics for Windows release 22.0 (IBM Corporation, 2013).
Results
Demographics
Across 2010-2015, 4,122 participants were recruited and interviewed for the EDRS, of which 529 were repeat participants (see Supplementary Material, Table 7 ). Sixty-four percent of the entire RPU cohort were male with a mean age of 23.6 years (SD 6.2; range 16-64), 97% were of English speaking background, 47% were tertiary qualified, 69% were employed in some capacity, 32% were students, 16% were unemployed and 3% were currently in drug treatment. Twelve percent of the 2010-2015 cohort identified as gay, lesbian, bisexual or transgendered (GLBT). More detailed demographics of each year's sample have been reported elsewhere (Sindicich & Burns, 2011 . Table 1) .
Rates of recent NPS use
Insert Table 1
Looking at the different classes of NPS (see Table 1 ), cathinones were originally the most prevalent NPS being used by participants, with almost one-fifth (18.5%) of RPU reporting recent (i.e. past six month) use in 2010. However, by 2015 this had declined significantly, with 7.7% reporting use of cathinones in the six months preceding interview (p<0.001). Conversely, in 2010 both phenethylamines and tryptamines had been used by 8% of RPU in the six months preceding interview; however, by 2015 rates of use had increased to 18.6% (p<0.001) and 10.9% (p=0.037) respectively, making them the two most commonly used groups of NPS in these years.
The use of synthetic cannabinoids was specifically asked about for the first time in 2011, with 6.6% of RPU reporting use within the six months preceding interview. This increased significantly in 2012 to 16.1% of the sample (p<0.001) and remained stable in 2013 (16.1%). However, in 2014 use of recent synthetic cannabinoids declined to rates observed in 2011 (6.9%; p<0.001), before stabilising in 2015 (6.4%).
The use of piperazines, plant-based NPS and aminoindanes remained uncommon across all years.
Specifically, from 2010-2015, the use of piperazines declined from 4.9% to 0% (p<0.001); plant-based NPS increased from 2.0% to 5.0% (p=0.005); and there was no change in the use of aminoindanes or arylcyclohexylamines.
These trends remained consistent even when repeat participants were excluded (see Supplementary Material, Table 8 ).
Correlates of NPS use
Phenethylamines
At the bivariate level, RPU who reported recent phenethylamine use were more likely to be under the age of 25 (OR 3.41, p<0.001), male (OR 1.67, p=0.001), report weekly or more ecstasy use (OR 1.86, p<0.001), report recent (i.e., past six month) LSD use (OR 3.06, p<0.001) , and report recent use of a greater number of drug classes (p<0.001), when compared to RPU who had not used any NPS in the preceding six months.
When significant bivariate correlates were entered into a multivariable logistic regression model (controlling for year), age, sex, weekly or more ecstasy use, recent LSD use and greater levels of poly drug use remained significant. When the variables significant at the bivariate level were entered into a multivariable logistic regression model, controlling for year, the following variables remained significant; daily cannabis use, recent LSD use and greater levels of poly drug use.
Insert
Insert Table 3 
Synthetic cannabinoids
At the bivariate level, RPU who reported recent use of synthetic cannabinoids were more likely to report daily tobacco use (OR 1.76, p=0.001), daily cannabis use (OR 2.74, p<0.001), and past month criminal activity (OR 2.10, p<0.001), when compared to RPU who had not used any NPS in the preceding six months. Conversely, recent cocaine users were less likely to report recent use of synthetic cannabinoids (OR 0.46, p=0.001) .
When the variables significant at the bivariate level were entered into a multivariable logistic regression model, controlling for year, the following variables were significant; daily cannabis use, recent cocaine use, past month criminal activity and greater levels of poly drug use.
Insert Table 4 3.
Synthetic cathinones
No variables were significantly correlated with recent synthetic cathinone use at the bivariate level.
When a multivariable logistic regression was conducted (controlling for year), daily tobacco use and greater levels of poly drug use were found to be significantly associated with recent synthetic cathinone use. Cocaine use was also associated with recent synthetic cathinone use, although this did not reach statistical significance. Insert Table 6 4. Discussion Despite fluctuations in use of specific forms over the past six years, the use of NPS has been established as a significant and ongoing practice amongst cross-sectional samples of RPU in Australia. Whilst it is difficult to make any direct comparisons to other studies (particularly given differences in time frames, samples and categorisations of NPS), it does appear that the changes noted in our sample mirror a number of international trends (European Commission, 2014; Home Office, 2014; Miech et al., 2014) . Indeed, the globalisation of drug marketplaces has increased the accessibility and volatility of drugs such as NPS (Griffiths et al., 2010) , and it is essential that projects such as the EDRS continue to monitor these substances so that changing trends can be detected in a timely manner.
Insert
It is unknown what might be driving the specific trends observed in this paper; however, consumer acceptability and legislative changes are factors to consider. In 2013, EDRS participants were asked to rate the positive, negative and hangover effects of NPS, and how likely they would be to consume the substance again. DMT and 2CB received the highest ratings for pleasurability and likelihood to take again, whilst mephedrone and synthetic cannabinoids were viewed less favourably and reportedly had worse side effects (Matthews et al., 2013; Sindicich & Burns, 2014) . Similarly, a selfselecting online sample of DMT and NBOMe users found that when compared to other hallucinogens (i.e. LSD, magic mushrooms and ketamine) both DMT and NBOMe were rated favourably in terms of strength of effect and pleasurability (Lawn et al., 2014; .
In contrast, a global study of dual 'natural' and synthetic cannabis users found that 93% of participants preferred natural cannabis over synthetic cannabis (Winstock & Barratt, 2013) . It seems likely that our sample of RPU experimented with a range of NPS, continuing to use those deemed 'acceptable' in terms of their psychopharmacological and side effects, and ceasing use of those that were not. This theory is supported by findings that DMT, 2C-x and NBOMe remain the most commonly sold NPS on dark net marketplaces (Van Buskirk et al., 2015) , however, it would be of benefit for future research to explicitly test this hypothesis through a close examination of the motivations for consuming specific NPS.
Another factor to consider is the impact of legislative changes. Given the varying legislative frameworks across jurisdictions and the different dates of implementation, it is beyond the scope of this paper to determine whether the scheduling of NPS may have contributed to the trends observed in this paper. For example, in 2012, the Australian Therapeutic Goods Administration introduced a blanket ban on any type of synthetic cannabinoid that produced the same pharmacological effect as cannabis (Bright et al., 2013) . In 2014 there was a significant decline in the use of synthetic cannabinoids amongst our sample of RPU; however, it is unclear if this was a lagged effect of the legislation (due to practices such as stockpiling) or if it was due to other, unrelated factors such as consumer acceptability. Given that this is a sample of illicit drug users, it seems unlikely that the criminalisation of NPS use would have dissuaded use of these substances, although it would have reduced their availability. Furthermore, legislative changes fail to explain the increase in phenethylamines and tryptamines observed in this paper. Nevertheless, it is important that further research evaluate the impact of Australian legislation on the NPS marketplace to provide an evidence-base for the efficacy of these regulatory approaches.
This paper also illustrates the heterogeneity of NPS consumers, with the correlates of use varying across NPS classes. Perhaps not surprisingly, our findings suggest that RPU seek out NPS that have similar properties to the 'traditional' illicit drugs that they are already using. More specifically, frequent ecstasy users were more likely to report recent use of phenethylamine-type NPS, LSD users were more likely to report recent use of phenethylamines (many of which have psychedelic properties) and tryptamines, and daily cannabis users were more likely to report recent use of synthetic cannabinoids. Cocaine users were more likely to report recent use of synthetic cathinones, although this did not reach statistical significance.
Use of a larger number of 'established' illicit drugs emerged as the only consistent predictor of NPS use. This suggests that NPS users may represent a more innovative group of 'psychonaut' drug users, a term used to describe people who actively seek out new substances for the purposes of achieving altered states of consciousness (EMCCDA, 2004) . It is important to note that for participants using a single NPS class this did not equate to a greater likelihood of drug-related harms. This was somewhat surprising, particularly given that clinical studies have shown that drugs such as NBOMe have been linked to a number of deaths and hospitalisations, despite its short history of human consumption (Wood et al., 2015) .
Rather, poly-NPS users were found to be the riskiest group of NPS consumers; in addition to having high levels of poly-drug use, this group were also more likely to have engaged in past month criminal activity and to have overdosed on any drug in the past year. These behaviours carry serious public health implications, particularly given the ever increasing number of NPS being identified, the limited knowledge of the short-and long-term effects of these drugs, and a lack of information on how they interact with other drugs. It is recommended that credible harm reduction messages be disseminated amongst these populations, with a particular focus on the potential risks of combining NPS and 'traditional' illicit drugs (for example, see Winstock et al., 2010) .
Limitations
This study has certain limitations. Firstly, the EDRS sample is not representative, which means that our findings are not generalizable to all RPU in Australia. Rather, it is a sentinel sample which allows for the early identification of trends in illicit drug markets, which is particularly important when monitoring marketplaces which are rapidly changing (as is the case of NPS). Secondly, our analysis is reliant upon self-report data from participants which may be subject to bias. Although evidence points to sufficient validity and reliability of self-report in studies assessing illicit drug use (Darke, 1998) , it is possible that participants may have incorrectly identified the NPS being consumed (i.e. it may have been sold to them as one thing, but have been something else) and it would be of benefit for future studies to corroborate their findings through chemical analysis. Finally, the EDRS only specifically asked about 26 different NPS and as such rates of use may be underestimated.
Conclusions
Whilst NPS use has been established as a significant and ongoing practice amongst our sample of RPU, it remains a highly dynamic marketplace with the popularity of NPS classes changing significantly across 2010-2015. It appears that RPU seek out NPS with similar properties to the traditional illicit drugs that they are already consuming. Poly NPS consumers were found to be a particularly high risk group and as such it is essential that credible harm reductions messages be distributed amongst these populations.
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